In Q4 2025, Charles River generated $994227000 in revenue, down 0.8% year-over-year. The company reported a GAAP net loss of $276555000 and operating loss of $283440000, primarily due to intangible asset and goodwill impairments, while non-GAAP EPS was $2.39.

Charles River Laboratories posted Q3 2025 revenue of $1.00 billion, down 0.5% YoY, with GAAP net income falling to $54.4 million. Despite headwinds, the company saw strength in Research Models and Services. Guidance was tightened, reflecting cautious optimism.

Charles River Laboratories delivered a solid second-quarter financial performance, with revenue reaching $1.03 billion, a slight increase of 0.6% year-over-year. The company reported GAAP EPS of $1.06 and non-GAAP EPS of $3.12, demonstrating progress towards organic revenue growth, particularly driven by favorable results in the Discovery and Safety Assessment (DSA) segment. Operating margins improved on a non-GAAP basis across all segments, partially offset by higher unallocated corporate costs.

Charles River Laboratories posted Q1 2025 revenue of $984.2M, down 2.7% YoY, with a GAAP EPS of $0.50 and non-GAAP EPS of $2.34. Despite lower revenue across all segments, non-GAAP operating margins improved due to cost-saving measures. The company raised its FY25 guidance slightly, citing improved DSA bookings.

Charles River Labs reported Q4 2024 revenue of $1.00 billion, a 1.1% YoY decline, primarily due to weak performance in the DSA and RMS segments. The company posted a GAAP net loss of $215.7 million, largely driven by a $215 million goodwill impairment in the Biologics Solutions unit. However, non-GAAP earnings per share increased by 8.1% YoY, supported by cost reductions and higher Manufacturing segment revenue.

Charles River Laboratories reported a revenue of $1.01 billion for Q3 2024, a 1.6% decrease compared to Q3 2023. GAAP EPS was $1.33, while non-GAAP EPS was $2.59. The company is navigating a challenging period with biopharmaceutical clients reducing spending, but biotech funding has improved, showing early signs of stabilization.

Charles River Laboratories reported a 3.2% decrease in second-quarter revenue to $1.03 billion, driven by declines in Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, partially offset by growth in Manufacturing Solutions. GAAP EPS was $1.74, while non-GAAP EPS was $2.80. The company revised its 2024 guidance due to softer demand trends, particularly from biopharmaceutical clients.

Charles River Laboratories reported a Q4 2023 revenue of $1.01 billion, a 7.9% decrease compared to Q4 2022. GAAP earnings per share were $3.62, while non-GAAP earnings per share were $2.46. The company's performance reflected moderating demand trends in the life sciences sector.

Charles River Laboratories reported a 3.8% increase in revenue to $1.03 billion for the third quarter of 2023. GAAP earnings per share decreased by 10.1% to $1.69, while non-GAAP earnings per share increased by 3.4% to $2.72. The company updated its 2023 financial guidance, narrowing its revenue growth and non-GAAP EPS ranges.

Charles River Laboratories reported second-quarter revenue of $1.06 billion, an 8.9% increase year-over-year. GAAP earnings per share were $1.89, while non-GAAP earnings per share were $2.69. The company has updated its 2023 guidance to reflect a solid first half performance.

Charles River Laboratories announced first-quarter 2023 results with revenue of $1.03 billion, a 12.6% increase from Q1 2022. GAAP EPS was $2.01 and Non-GAAP EPS was $2.78. The company updated its 2023 guidance to reflect the strong first-quarter performance.

Charles River Laboratories announced its Q4 and full-year 2022 results, with Q4 revenue reaching $1.10 billion, a 21.5% increase year-over-year. GAAP EPS was $3.65, and non-GAAP EPS was $2.98. The company provided 2023 guidance, noting challenges with NHP supply but solid business fundamentals.

Charles River Laboratories reported third-quarter results with revenue of $989.2 million, a 10.4% increase year-over-year. GAAP earnings per share were $1.88, a decrease of 6.5% from the prior year, while non-GAAP earnings per share were $2.63, a decrease of 2.6%. The company narrowed its 2022 revenue growth and earnings per share guidance and announced a planned divestiture of its Avian Vaccine business.

Charles River Laboratories reported a 6.4% increase in revenue for the second quarter of 2022, reaching $973.1 million. GAAP earnings per share were $2.13, and non-GAAP earnings per share were $2.77. The company has reduced its 2022 financial guidance due to headwinds in the CDMO business, unfavorable foreign exchange rates and rising interest rates.

Charles River Laboratories International, Inc. reported first-quarter revenue of $913.9 million, a 10.8% increase from the first quarter of 2021. GAAP earnings per share were $1.81, and non-GAAP earnings per share were $2.75. The company updated its 2022 financial guidance, increasing reported revenue growth guidance by 50 basis points.

Charles River Laboratories International, Inc. reported Q4 2021 revenue of $905.1 million, a 14.4% increase year-over-year. GAAP EPS was $2.67, and non-GAAP EPS was $2.49. The company reaffirmed its 2022 guidance.

Charles River Laboratories reported a strong third quarter with revenue of $895.9 million, a 20.5% increase from the third quarter of 2020. GAAP earnings per share were $2.01, while non-GAAP earnings per share were $2.70. The company updated its 2021 financial guidance to reflect recent divestitures and foreign exchange impacts.

Charles River Laboratories reported strong second-quarter results, with revenue of $914.6 million, a 34.0% increase year-over-year. GAAP earnings per share were $1.72, and non-GAAP earnings per share were $2.61. The company also increased its 2021 financial guidance due to sustained demand.

Charles River Laboratories reported a strong first quarter in 2021, with revenue reaching $824.6 million, a 16.6% increase compared to the first quarter of 2020. GAAP earnings per share were $1.20, a 17.6% increase year-over-year, and non-GAAP earnings per share were $2.53, a 37.5% increase year-over-year. The company also updated its 2021 guidance, reflecting confidence in continued client demand.

Charles River Laboratories reported a strong fourth quarter with revenue of $791.0 million, a 14.4% increase year-over-year. GAAP earnings per share were $2.81, and non-GAAP earnings per share were $2.39. The company also provided 2021 guidance and announced a definitive agreement to acquire Cognate BioServices.

Charles River Laboratories reported strong third-quarter results with revenue of $743.3 million, an 11.3% increase from the previous year. GAAP earnings per share were $2.03, and non-GAAP earnings per share were $2.33. The company also increased its 2020 financial guidance.

Charles River Laboratories reported second-quarter revenue of $682.6 million, a 3.8% increase year-over-year. GAAP earnings per share were $1.34, while non-GAAP earnings per share were $1.58. The company increased its 2020 guidance and announced the proposed acquisition of Cellero.

Charles River Laboratories announced strong Q1 2020 results, with revenue up 17.0% year-over-year to $707.1 million and non-GAAP EPS up 31.4% to $1.84. However, GAAP EPS decreased by 8.1% to $1.02 due to venture capital investment losses. The company revised its 2020 guidance due to the expected impact of the COVID-19 pandemic, anticipating a reduction in revenue of approximately $135 to $215 million.

Charles River Laboratories reported a strong fourth quarter with revenue of $691.1 million, a 14.9% increase year-over-year. GAAP EPS was $1.61 and non-GAAP EPS was $2.01. The company's performance was driven by the breadth of its early-stage portfolio and investments in scientific capabilities.